OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades

OptimizeRx Corp (NASDAQ:OPRX) is one of the best performing micro cap stocks in 2025. On January 5, Stifel Nicolaus analyst David Grossman reaffirmed a Buy rating on OptimizeRx with a $21 price target. Just days earlier, on December 23, Lake Street analyst Eric Martinuzzi also reiterated a Buy rating on the stock, setting a $24 price target. OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades everything possible/Shutterstock.com On December 17, OptimizeRx Corp (NASDAQ ...